Iron Deficiency Anemia: IV Iron Formulations and Indications
Sam Anderson
Diagnosis: Ferritin Thresholds and Confounders
Iron deficiency is the most common nutritional deficiency worldwide, and iron deficiency anemia has a significant impact on functional capacity, cognitive performance, and quality of life. For the hematologist, gastroenterologist, internist, or primary care physician managing iron-deficient patients, the treatment landscape has evolved substantially with the availability of modern IV iron formulations that can safely replete iron stores in one or two infusion visits. Understanding the diagnostic thresholds, IV iron indications, and comparative safety of available formulations is essential for evidence-based management.
Serum ferritin remains the most useful initial test, with a threshold below 30 ng/mL providing sensitivity of 92% and specificity of 98% for iron deficiency in otherwise healthy adults[2]. However, ferritin is an acute-phase reactant that rises with inflammation, infection, liver disease, and malignancy. In inflammatory states, a ferritin below 100 ng/mL combined with transferrin saturation below 20% identifies iron deficiency with reasonable accuracy. Soluble transferrin receptor (sTfR) and the sTfR/log ferritin index are less affected by inflammation and improve diagnostic accuracy in complex patients (AUC 0.95 versus 0.85 for ferritin alone). Reticulocyte hemoglobin content (CHr below 28 pg) provides a real-time snapshot of iron-restricted erythropoiesis.
Oral Iron: Optimization Strategies
Ferrous sulfate 325 mg (65 mg elemental iron) every other day is now preferred over daily or multiple daily dosing, based on the landmark hepcidin studies by Moretti et al. (2015) showing that alternate-day dosing increases fractional iron absorption by 34% compared to twice-daily dosing while reducing GI side effects[2]. Absorption is maximized by taking on an empty stomach with vitamin C (200 mg). GI side effects affect 30-50% of patients on conventional regimens, driving non-adherence. Ferric maltol (30 mg twice daily) offers improved tolerability with comparable efficacy, achieving hemoglobin normalization in 65% of IBD patients at 12 weeks in the AEGIS study[4].
Indications for Intravenous Iron
IV iron is indicated for oral iron intolerance or nonadherence, malabsorption (celiac disease, post-bariatric surgery, IBD), ongoing blood loss exceeding oral repletion capacity, hemoglobin below 7 g/dL requiring rapid correction, chronic kidney disease on ESA therapy, and heart failure with iron deficiency (ferritin below 100 or ferritin 100-299 with TSAT below 20%). The AFFIRM-AHF trial demonstrated that IV ferric carboxymaltose (FCM) reduced recurrent heart failure hospitalizations by 26% (RR 0.74, 95% CI 0.58-0.94) in patients with HFrEF and iron deficiency, even without anemia[1].
IV Iron Formulations: Comparative Guide
Ferric carboxymaltose (Injectafer) allows up to 750 mg per infusion (15 mg/kg) in 15-30 minutes, with 2 doses 7 days apart for total repletion up to 1,500 mg. Ferric derisomaltose (Monoferric) permits single-session repletion up to 1,000-1,500 mg in 20-60 minutes[3], making it the most convenient option. Iron sucrose (Venofer) requires multiple 200-300 mg doses over 2-3 weeks and is the most established agent in CKD. Low-molecular-weight iron dextran allows single-dose total repletion (up to 1,000 mg in 60 minutes) but carries a slightly higher anaphylaxis risk. The rate of serious infusion reactions across all modern IV iron formulations is 0.02-0.04% per infusion, comparable to IV antibiotics.
Monitoring and Hypophosphatemia Risk
Post-IV iron monitoring includes CBC and ferritin at 4-8 weeks (earlier measurement overestimates stores). Ferric carboxymaltose carries a unique risk of hypophosphatemia through FGF23 elevation: the PHOSPHARE-IDA trials documented hypophosphatemia (below 2 mg/dL) in 50-75% of patients receiving FCM versus 8% with ferric derisomaltose[3]. Symptomatic hypophosphatemia (fatigue, bone pain, myopathy) is clinically significant in 10-15% and can persist for weeks. Phosphate monitoring at 2 weeks post-infusion is recommended for FCM, particularly with repeated dosing. Ferric derisomaltose is preferred when repeated infusions are anticipated or in patients at risk for phosphate depletion (vitamin D deficiency, malabsorption). See our review of CKD-MBD phosphate management for related monitoring considerations.
The FCM-Versus-Derisomaltose Decision
When IV iron is indicated, the choice between ferric carboxymaltose and ferric derisomaltose hinges largely on two factors: dosing convenience and hypophosphatemia risk. Derisomaltose offers the simplest regimen — up to 1,500 mg in a single 20-60 minute infusion versus FCM's two-visit protocol. But the more clinically significant differentiator is the PHOSPHARE-IDA data showing FCM causes hypophosphatemia in 50-75% of patients compared to 8% with derisomaltose. For the patient who needs a single infusion and will not be followed with phosphate monitoring — the typical outpatient scenario — derisomaltose is the pragmatic choice. For the patient already established on FCM with good response and no phosphate issues, there is no reason to switch. And for the heart failure patient, FCM has the AFFIRM-AHF outcomes data showing the 26% reduction in recurrent HF hospitalizations; whether derisomaltose provides equivalent cardiovascular benefit is plausible but unproven in a dedicated trial.
Limitations and the Cause-Finding Imperative
Repleting iron — whether orally or intravenously — is the treatment, not the diagnosis. Every iron-deficient patient deserves an evaluation for the underlying cause, and the most common clinical error is treating the deficiency without investigating why it occurred. In premenopausal women, menstrual blood loss is the most frequent cause and may require gynecologic evaluation if heavy. In postmenopausal women and men, GI blood loss must be excluded — this means at minimum a fecal occult blood test and, in many cases, upper and lower endoscopy. The patient who receives IV iron repletion, feels better, and is discharged without a plan to identify the source of loss will inevitably become iron-deficient again. The infusion treats the consequence; finding and addressing the cause prevents recurrence.
References
- Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial PubMed 33197395
- Iron absorption from oral iron supplements given on consecutive versus alternate days and as single morning doses versus twice-daily split doses in iron-depleted women: two open-label, randomised controlled trials PubMed 26289639
- PHOSPHARE-IDA: a randomized, open-label trial of ferric derisomaltose versus ferric carboxymaltose in iron deficiency anaemia PubMed 34850000
- Efficacy and safety of ferric maltol for iron deficiency anaemia in inflammatory bowel disease PubMed 36513444
Frequently Asked Questions
What ferritin threshold diagnoses iron deficiency in inflammatory states?
Is alternate-day oral iron dosing better than daily?
What are the indications for IV iron over oral iron?
Which IV iron formulation allows single-session complete repletion?
Does ferric carboxymaltose cause hypophosphatemia?
When should post-IV iron labs be checked?
Explore This Topic in Ailva
Ailva is a free clinical intelligence platform for NPI-verified US physicians. Get evidence-based answers with verified citations from 16M+ indexed papers — plus free CME credits.
Founder of Ailva.ai | Former Director of Research and Author of 200+ Medically Reviewed Articles | Editor-in-Chief of EudaLife Magazine